{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T08:23:04Z","timestamp":1768638184758,"version":"3.49.0"},"reference-count":24,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,4,26]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Despite of recent advancement in the burns wound management, burn wound infection (BWI) is still one of the major cause of burns mortality. Patients who survive their burns injury still suffers from BWI related complication like delayed wound healing and poor scarring. BWI has been treated by application of topical antimicrobial agents or systemic antibiotics. Due to the global risk of developing systemic antibiotics resistance, medical research focuses on identifying single topical agent which has effective antimicrobial activity, easily available and cost effective. One such agent is acetic acid (AA). AA has been used as a topical antibacterial agent for the treatment of burns wounds for many years and has shown to have activity against gram-negative organisms including\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      . So far there has been no consensus on optimal concentration that has effective antimicrobial activity, frequency of application, duration of treatment and most importantly good patient\u2019s tolerability. A randomised control study is required to answer all these questions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the efficacy and tolerability of 0.5% and 2% of AA when applied to colonised burns wounds for 3\u2009days after admittance to the Queen Elizabeth Hospital Birmingham.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This is a double-blinded, prospective, randomised, controlled, single-centre trial. Patients will be screened for eligibility in the inpatient area and those who are found to be eligible will be randomly assigned to one of two treatment groups: group 1: 0.5% AA (10 patients); group 2: 2% AA (10 patients); total number: 20 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Primary outcome<\/jats:italic>\n                      : Efficacy will be assessed by measuring the bacterial load from microbiology wound swabs for three consecutive days.\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:italic>Secondary outcomes<\/jats:italic>\n                      : (1) The assessment of antimicrobial activity of AA and the minimum inhibitory concentrations. (2) Patient\u2019s tolerance by assessing Visual Analogue Scale pain score. (3) Time to 95% wound healing of treatment area. (4) Patient\u2019s perceived treatment allocation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>AceticA trial protocol was approved by the National Research Ethics Service (West Midlands\u2014Edgbaston Research Ethics Committee; 17\/WM\/0407; IRAS 234132). This article refers to protocol version 5.0 dated 6 July 2020. The analysed results will be presented at national and international conferences related to management of burn patients. The generated articles based on the trial results will be submitted to peer review journals for publication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN11636684\">ISRCTN11636684<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-058006","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T13:10:38Z","timestamp":1695647438000},"page":"e058006","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and optimal dose of acetic acid to treat colonised burns wounds: protocol for a pilot randomised controlled trial"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"isrctn11636684","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1641-2478","authenticated-orcid":false,"given":"Rizwana","family":"Imran","sequence":"first","affiliation":[{"name":"Burn Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"},{"name":"Scar Free Foundation Burn Research Centre, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek","family":"Hassouna","sequence":"additional","affiliation":[{"name":"Burn Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"},{"name":"Scar Free Foundation Burn Research Centre, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurneet","family":"Sur","sequence":"additional","affiliation":[{"name":"Cancer Research Clinical Trials Unit (CRCTU), Devices, Drugs, Diagnostics and Biomarkers (D3B), University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Casey","sequence":"additional","affiliation":[{"name":"Cancer Research Clinical Trials Unit (CRCTU), Devices, Drugs, Diagnostics and Biomarkers (D3B), University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Homer","sequence":"additional","affiliation":[{"name":"Cancer Research Clinical Trials Unit (CRCTU), Devices, Drugs, Diagnostics and Biomarkers (D3B), University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren","family":"Barton","sequence":"additional","affiliation":[{"name":"Cancer Research Clinical Trials Unit (CRCTU), Devices, Drugs, Diagnostics and Biomarkers (D3B), University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian","family":"Brock","sequence":"additional","affiliation":[{"name":"Cancer Research Clinical Trials Unit (CRCTU), Devices, Drugs, Diagnostics and Biomarkers (D3B), University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Altarrah","sequence":"additional","affiliation":[{"name":"Burn Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"},{"name":"Scar Free Foundation Burn Research Centre, Birmingham, UK"},{"name":"Institute of Inflammation and Ageing, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naiem","family":"Moiemen","sequence":"additional","affiliation":[{"name":"Burn Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"},{"name":"Scar Free Foundation Burn Research Centre, Birmingham, UK"},{"name":"Institute of Inflammation and Ageing, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,9,25]]},"reference":[{"key":"2025121219392169000_13.9.e058006.1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/BCR.0B013E31814B25B1","article-title":"National burn repository 2006: A ten-year review","volume":"28","author":"Latenser","year":"2007","journal-title":"Journal of Burn Care & Research"},{"key":"2025121219392169000_13.9.e058006.2","doi-asserted-by":"publisher","DOI":"10.1097\/BCR.0b013e318234966c"},{"key":"2025121219392169000_13.9.e058006.3","first-page":"124","article-title":"Burn wound infections: Current status","volume":"22","year":"1998","journal-title":"World J Surg"},{"key":"2025121219392169000_13.9.e058006.4","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/01.TA.0000044565.69410.95","article-title":"Survival benefit conferred by topical antimicrobial preparations in burn patients: a historical perspective","volume":"56","author":"Brown","year":"2004","journal-title":"The Journal of Trauma: Injury, Infection, and Critical Care"},{"key":"2025121219392169000_13.9.e058006.5","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.19.2.403-434.2006"},{"key":"2025121219392169000_13.9.e058006.6","unstructured":"Global action plan on antimicrobial resistance [Internet] .ISBN 978 92 4 150976 3."},{"key":"2025121219392169000_13.9.e058006.7","unstructured":"World health Organisation. World health organization model list of essential Medicines:21St list 2019. 2019."},{"key":"2025121219392169000_13.9.e058006.8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0140-6736(68)90004-4","article-title":"Acetic acid in the treatment of superficial wounds infected by Pseudomonas Aeruginosa","volume":"1","author":"Phillips","year":"1968","journal-title":"Lancet"},{"key":"2025121219392169000_13.9.e058006.9","doi-asserted-by":"crossref","DOI":"10.1016\/0140-6736(92)92483-V","article-title":"Acetic acid to treat Pseudomonas Aeruginosa in superficial wounds and burns","volume":"340","author":"Milner","year":"1992","journal-title":"Lancet"},{"key":"2025121219392169000_13.9.e058006.10","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jama.1916.02590220040013","article-title":"Treatment of Bacillus Pyocyaneus infection","volume":"LXVII","author":"Taylor","year":"1916","journal-title":"JAMA"},{"key":"2025121219392169000_13.9.e058006.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2013.05.001"},{"key":"2025121219392169000_13.9.e058006.12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246020","article-title":"Antibiofilm and Antipersister activity of acetic acid against extensively drug resistant Pseudomonas Aeruginosa Paw1","volume":"16","author":"Tawre","year":"2021","journal-title":"PLoS One"},{"key":"2025121219392169000_13.9.e058006.13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0140-6736(68)90004-4","article-title":"Acetic acid in the treatment of superficial wounds infected by Pseudomonas Aeruginosa","volume":"1","author":"Phillips","year":"1968","journal-title":"Lancet"},{"key":"2025121219392169000_13.9.e058006.14","doi-asserted-by":"publisher","DOI":"10.1136\/jramc-139-02-04"},{"key":"2025121219392169000_13.9.e058006.15","doi-asserted-by":"publisher","DOI":"10.1136\/jramc-139-02-04"},{"key":"2025121219392169000_13.9.e058006.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.burns.2008.11.009"},{"key":"2025121219392169000_13.9.e058006.17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0195-6701(97)90201-2","article-title":"Acetic acid treatment of Pseudomonal postoperative wound infection","volume":"36","author":"Nagoba","year":"1997","journal-title":"Journal of Hospital Infection"},{"key":"2025121219392169000_13.9.e058006.18","first-page":"1","article-title":"Management of Pseudomonal wound infection","volume":"20","author":"Salati","year":"2008","journal-title":"IJS"},{"key":"2025121219392169000_13.9.e058006.19","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/iwj.12428","article-title":"Efficacy of 1% acetic acid in the treatment of chronic wounds infected with Pseudomonas Aeruginosa: prospective randomised controlled clinical trial","volume":"13","author":"Madhusudhan","year":"2016","journal-title":"Int Wound J"},{"key":"2025121219392169000_13.9.e058006.20","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.burns.2021.07.011","article-title":"Acetic acid dressings used to treat Pseudomonas Colonised burn wounds: A UK national survey","volume":"48","author":"Nour","year":"2022","journal-title":"Burns"},{"key":"2025121219392169000_13.9.e058006.21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136190","article-title":"The Antibacterial activity of acetic acid against Biofilm-producing pathogens of relevance to burns patients","volume":"10","author":"Halstead","year":"2015","journal-title":"PLoS One"},{"key":"2025121219392169000_13.9.e058006.22","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.burns.2015.06.005","article-title":"Antimicrobial dressings: comparison of the ability of a panel of dressings to prevent Biofilm formation by key burn wound pathogens","volume":"41","author":"Halstead","year":"2015","journal-title":"Burns"},{"key":"2025121219392169000_13.9.e058006.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.burns.2009.08.007"},{"key":"2025121219392169000_13.9.e058006.24","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jiph.2013.05.005","article-title":"Acetic acid treatment of Pseudomonal wound infections--a review","volume":"6","author":"Nagoba","year":"2013","journal-title":"Journal of Infection and Public Health"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-058006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T03:39:30Z","timestamp":1765597170000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-058006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,25]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/bmjopen-2021-058006"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-058006","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}